Advertisement

Schizophrenia and oestrogens — is there an association?

  • Anita Riecher-Rössler
  • Heinz Häfner
Original Articles

Summary

Some early psychiatrists already believed that schizophrenic disorders were associated with a disturbed balance of sexual hormones. This belief was based on the observation of a. an “insufficient functioning of the sexual glands” with so-called “hypoestrogenism”, and b. an influence of ovarian function on schizophrenic psychoses. As this review shows, there are findings from recent research which seem to confirm that estrogens may have a protective effect in schizophrenia. There are also occasional hints at a possible “hypoestrogenism” in schizophrenia. In our own epidemiological, clinical and animal studies the hypothesis of a protective effect of oestrogens was for the first time systematically examined and confirmed. Oestrogens seem to modulate the sensitivity of D2-receptors in the brain, and clinically they seem to have a neuroleptic-like effect. These findings may have important implications for the prevention and therapy of schizophrenic disorders. Furthermore, our findings indicate the need to reinvestigate the question of a disturbed balance of sexual hormones in schizophrenic disorders. Further research on the role of oestrogens in schizophrenic disorders could in our opinion contribute to understanding the still unclear, possibly aetiologically heterogeneous pathogenetic mechanism of schizophrenic psychoses.

Key words

Schizophrenia Oestrogens Ovarian function Menstrual cycle Menopause 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baruk H, Melzer R, Vezous A, Farjeat J (1950) L'effondrement oestrogénique dans la démence precoce. Etude par la méthode des frottis vaginaux de Papanicolaou. Ann of Medical Psychol (Paris) 108:181–187Google Scholar
  2. Bédard P, Langelier P, Villeneuve A (1977) Estrogens and the Extrapyramidal System. Lancet II:1367–1368CrossRefGoogle Scholar
  3. Bédard P, Boucher R, Daigle M, DiPaolo T (1984) Similar effect of estradiol and haloperidol on experimental tardive dyskinesia in monkeys. Psychoneuroendocrinology 9:375–379CrossRefPubMedGoogle Scholar
  4. Beumont PJ, Gelder MG, Friesen HG, Harris GW, McKinnon PC, Mandelbrote BM, Wiles DH (1974) The effects of phenothiazines on endocrine function: Patients with inappropriaqte lactation and amenorrhea. Br J Psychiatry 124:413–419PubMedGoogle Scholar
  5. Bleuler M (1943) Die spätschizophrenen Krankheitsbilder. Neurologie XV, 9:259–290Google Scholar
  6. Brambilla F, Guerrini A, Guastalla A, Rovere C, Riggi F (1975) Neuroendocrine Effect of Haloperidol Therapy in Chronic Schizophrenia. Psychopharmacologia 44:17–22CrossRefPubMedGoogle Scholar
  7. Brambilla F (1980) Neuroendocrine function in schizophrenia. Acta Psychiatria Belg 80:421Google Scholar
  8. Carlsson A (1987) The dopamine hypothesis of schizophrenia 20 years later. In: Häfner H; Gattaz WF; and Janzarik W (eds) Search for the causes of schizophrenia. Springer, Berlin Heidelberg New York, pp 223–235Google Scholar
  9. Chang SS, Renshaw DC (1986) Psychosis and pregnancy. Compr Ther 12:36–41Google Scholar
  10. Collu R, Jequier JC, Leboeuf J, Ducharme JR (1977) Endocrine effects of pimozide, a specific dopaminergic blocker. J Endocrinol Metab 44:981–948Google Scholar
  11. Cookson JC (1981) Oestrogens, dopamine and mood. Br J Psychiatry 139:365PubMedGoogle Scholar
  12. Czernik A, Kleesiek K (1979) Die Wirkung von Depotneuroleptika auf die Hormonsekretion des Hypophysen-Vorderlappens. Nervenarzt 50:527–533PubMedGoogle Scholar
  13. Diczfalusy E, Lauritzen C (1961) Östrogene beim Menschen. Springer, Berlin Göttingen HeidelbergGoogle Scholar
  14. Diedrich K, Wildt L (1990) Neue Wege in Diagnostik und Therapie der Sterilität. Enke, StuttgartGoogle Scholar
  15. DiPaolo T, Payet P, Labrie F (1981) Effect of chronic estradiol and haloperidol treatment on striatal dopamine receptors. Eur J Pharmacol 73:105–106CrossRefPubMedGoogle Scholar
  16. Dupont A, DiPaolo T, Gagne B, Barden N (1981) Effects of chronic estrogen treatment on dopamine concentrations and turnover in discrete brain nuclei of ovariectomized rats. Neurosci Let 22:69–74CrossRefGoogle Scholar
  17. Endo M, Daiguji M, Asano Y, Yamashita I, Takahashi S (1978) Periodic Psychosis recurring in Association with Menstrual Cycle. J Clin Psychiatry 39:456–466PubMedGoogle Scholar
  18. Ferrier IN, Johnstone EC, Crow TJ, Rinzcon-Rodriguez I (1983) Anterior pituitary hormone secretion in chronic schizophrenics: responses to administration of hypothalamic releasing hormones. Arch Gen Psychiatry 40:755PubMedGoogle Scholar
  19. Foreman MM, Porter JC (1980) Effects of catechol estrogens and catecholamines on hypothalamic and corpus striatal tyrosine hydroxylase activity. J Neurochem 34:1175–1183PubMedGoogle Scholar
  20. Gattaz WF, Behrens S, De Vry J, Häfner H (1991) Östradiol hemmt Dopamin-vermittelte Verhaltensweisen bei Ratten: ein Tiermodell zur Untersuchung der geschlechtsspezifischen Unterschiede bei der Schizophrenie. Fortschr Neurol Psychiatr 1:1–44Google Scholar
  21. Geller EC (1923) Über Eierstocksfunktion bei Dementia praecox auf Grund anatomischer Untersuchungen. Arch Gynae 120:237CrossRefGoogle Scholar
  22. Glick J, Stewart D (1980) A new drug treatment for premenstrual exacerbation of schizophrenia. Compr Psychiatry 21:281–287CrossRefPubMedGoogle Scholar
  23. Goldstein MJ, Rodnick FH, Evans JR, May PRA, Steinberg MR (1978) Drugs and family therapy in the aftercare of acute schizophrenics. Arch Gen Psychiatry 35:1169–1177PubMedGoogle Scholar
  24. Gordon JH, Diamond BI (1981) Antagonism of dopamine supersensivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia. Biol Psychiatry 16:365–371PubMedGoogle Scholar
  25. Gordon JH, Borison RL, Diamond BI (1980) Modulation of dopamine receptor sensitivity by estrogen. Biol Psychiatry 15:389–396PubMedGoogle Scholar
  26. Häfner H (1987) Epidemiology of Schizophrenia. In: Häfner H, Gattaz WF, Janzarik W (eds) Search for the causes of schizophrenia, vol I. Springer, Berlin Heidelberg New YorkGoogle Scholar
  27. Häfner H, Riecher A, Maurer K, Löffler W, Munk-Jørgensen P, Strömgren E (1989) How does gender influence age at first hospitalization for schizophrenia? Psychol Med 19:903–918PubMedGoogle Scholar
  28. Häfner H, Behrens S, De Vry J, Gattaz WF, Löffler W, Maurer K, Riecher-Rössler A (1991a) Warum erkranken Frauen später an Schizophrenie? Erhöhung der Vulnerabilitätsschwelle durch Östrogen. Nervenheilk 10:154–163Google Scholar
  29. Häfner H, Behrens S, De Vry J, Gattaz WF (1991b) An animal model for the effects of estradiol on dopamine-mediated behaviour: implications for sex differences in schizophrenia. Psychiatry Res 38:125–134CrossRefPubMedGoogle Scholar
  30. Häfner H, Riecher-Rössler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, Fätkenheuer B, Löffler W, Heiden W an der (1991c) Geschlechtsunterschiede bei schizophrenen Erkrankungen. Fortsch Neurol Psychiatr 59:343–360Google Scholar
  31. Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF (1974) Drug and sociotherapy in the aftercare of schizophrenic patients. Arch Gen Psychiatry 31:603–618PubMedGoogle Scholar
  32. Holsboer F, Benkert O, Demisch L (1983) Changes in MAO activity during estrogen treatment of females with endogenous depression. Mod Probl Pharmacopsychiatry 19:321–326PubMedGoogle Scholar
  33. Hruska RE, Silbergeld EK (1980) Estrogen treatment enhances dopamine receptor sensitivity in the rat striatum. Eur J Pharmacol 61:397–400CrossRefPubMedGoogle Scholar
  34. Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S (1981) Clozapine: plasma levels and prolactin response. Psychopharmacology 73:184CrossRefPubMedGoogle Scholar
  35. Kendell RE, Chalmers JC, Platz C (1987) Epidemiology of puerperal psychoses. Br J Psychiatry 150:662–673PubMedGoogle Scholar
  36. Koller WC, Weiner WJ, Klawans HL, Nausieda PA (1980) Influence of female sex hormones on neuroleptic-induced behavioral supersensitivity. Neuropharmacology 19:387–391CrossRefPubMedGoogle Scholar
  37. Kraepelin E. (1909–1915) Psychiatrie, Bd 1–4. Barth, LeipzigGoogle Scholar
  38. Krafft-Ebing G von (1896) Untersuchungen über Irresein zur Zeit der Menstruation: Ein klinischer Beitrag zur Lehre vom periodischen Irresein. Arch Psychiatr 8:65–107CrossRefGoogle Scholar
  39. Kretschmer E (1921) Körperbau und Charakter. Untersuchungen zum Konstitutionsproblem und zur Lehre von den Temperamenten. 25th edition 1967. Springer, Berlin Heidelberg New YorkGoogle Scholar
  40. Lewine RRJ (1988) Gender and Schizophrenia. In: Nashrallah HA (ed) Handbook of schizophrenia, vol 3. Elsevier, New York, pp 121–136Google Scholar
  41. Lobo RA, Shoupe D, Roy S, Paul W (1984) Central and peripheral metabolites of norepinephrine and dopamine in postmenopausal women. Am J Obstet Gynecol 5:548–552Google Scholar
  42. Maggi A, Perez J (1985) Minireview: role of female gonodal hormones in the CNS; clinical and experimental aspects. Life Sci 37:893–906CrossRefPubMedGoogle Scholar
  43. Mall G (1959) Neuere Ergebnisse der Psycho-Endokrinologie. Ärztl Prax XI/40:1357–1360Google Scholar
  44. Mall G (1960) Diagnostik und Therapie ovarieller Psychosen. Zentralbl Gesamte Neurol Psychiatr 155:250Google Scholar
  45. Naber D, Ackenheil M, Laakman G, Fischer H, von Werder K (1980) Basal and stimulated levels of prolactin, TSH and LH in serum of chronic schizophrenic patients, long-term treated with neuroleptics. Pharmakopsychiatry 13:325–330Google Scholar
  46. Nicoletti F, Ferrara N, Patti F, Viglianesi M, Rampello L, Bianchi A, Reggio A, Scapagnini U (1983) Influence of sex steroids and prolactin on haloperidol-induced catalepsy. Brain Res 279:352–358CrossRefPubMedGoogle Scholar
  47. Nott PN (1982) Psychiatric illness following childbirth in Southampton: A case register study. Psychological Med 12:557–561Google Scholar
  48. Prentice DS, Deakin JFW (1992) Role of neuroleptic drugs and organic mechanism in the aetiology of menstrual irregularities in women. Schizophr Res 6(2):114CrossRefGoogle Scholar
  49. Riecher A, Maurer K, Löffler W, Fätkenheuer B, an der Heiden W, Häfner H (1989) Schizophrenia — a Disease of Young Single Males? Eur Arch Psychiatry Neuroll Sci 239:210–212CrossRefGoogle Scholar
  50. Riecher A, Maurer K, Löffler W, Fätkenheuer B, an der Heiden W, Munk-Jørgensen P, Strömgren E, Häfner H (1991) Sex differences in age at onset and course of schizophrenic disorders — a contribution to the understanding of the disease? In: Häfner H, Gattaz WF (eds) Search for the causes of schizophrenia, vol 2. Springer, Berlin Heidelberg New York, pp 14–33Google Scholar
  51. Riecher-Rössler A, Häfner H, Stummbaum M, Maurer K, Schmidt R (1993) Can estradiol modulate schizophrenic symptomatology? Schizophrenia Bull (in press)Google Scholar
  52. Seeman MV (1981) Gender and the Onset of Schizophrenia: Neurohumoral Influences. Psychiatr J Univ Ottawa 6:136–138Google Scholar
  53. Seeman MV (1983) Interaction of sex, age, and neuroleptic dose. Compr Psychiatry 24:125–128CrossRefPubMedGoogle Scholar
  54. Seeman MV, Lang M (1990) The role of estrogens in schizophrenia gender differences. Schizophrenia Bull 16:185–194PubMedGoogle Scholar
  55. Villeneuve A, Cazejust T, Cote M (1980) Estrogens in tardive dyskinesia in male psychiatric patients. Neuropsychobiology 6:145–151PubMedGoogle Scholar
  56. Wieck A (1989) Endocrine aspects of postnatal mental disorders. Baillière's Clinical Obstetrics and Gynaecology 3:857–877Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Anita Riecher-Rössler
    • 1
  • Heinz Häfner
    • 1
  1. 1.Central Institute of Mental HealthMannheim 1Germany

Personalised recommendations